In body fat mass matched male and female mice, treatment with GLP-1/GIP/glucagon triple agonism inhibited food intake, improved dyslipidemia, and decreased body weight and body fat mass in both groups, and reversed diet-induced steatohepatitis to a larger extent in female mice compared to male mice [211]. Here, GCG is linked to metabolic syndrome.